vs
Side-by-side financial comparison of Boston Scientific (BSX) and PG&E Corporation (PCG). Click either name above to swap in a different company.
PG&E Corporation is the larger business by last-quarter revenue ($6.9B vs $5.2B, roughly 1.3× Boston Scientific). Boston Scientific runs the higher net margin — 25.7% vs 12.9%, a 12.9% gap on every dollar of revenue. On growth, PG&E Corporation posted the faster year-over-year revenue change (15.0% vs 11.6%). Over the past eight quarters, Boston Scientific's revenue compounded faster (12.4% CAGR vs 7.2%).
Boston Scientific Corporation (BSC) is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Pacific Gas and Electric Company (PG&E) is an American investor-owned utility (IOU). The company is headquartered at Kaiser Center, in Oakland, California. PG&E provides natural gas and electricity to 5.2 million households in the northern two-thirds of California, from Bakersfield and northern Santa Barbara County, almost to the Oregon and Nevada state lines.
BSX vs PCG — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $5.2B | $6.9B |
| Net Profit | $1.3B | $885.0M |
| Gross Margin | 69.5% | — |
| Operating Margin | — | 21.4% |
| Net Margin | 25.7% | 12.9% |
| Revenue YoY | 11.6% | 15.0% |
| Net Profit YoY | 99.0% | 39.6% |
| EPS (diluted) | $0.90 | $0.39 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $5.2B | $6.9B | ||
| Q4 25 | $5.3B | $6.8B | ||
| Q3 25 | $5.1B | $6.3B | ||
| Q2 25 | $5.1B | $5.9B | ||
| Q1 25 | $4.7B | $6.0B | ||
| Q4 24 | $4.6B | $6.6B | ||
| Q3 24 | $4.2B | $5.9B | ||
| Q2 24 | $4.1B | $6.0B |
| Q1 26 | $1.3B | $885.0M | ||
| Q4 25 | $670.0M | $670.0M | ||
| Q3 25 | $755.0M | $850.0M | ||
| Q2 25 | $795.0M | $549.0M | ||
| Q1 25 | $672.0M | $634.0M | ||
| Q4 24 | $563.0M | $674.0M | ||
| Q3 24 | $468.0M | $579.0M | ||
| Q2 24 | $322.0M | $524.0M |
| Q1 26 | 69.5% | — | ||
| Q4 25 | 69.6% | — | ||
| Q3 25 | 69.9% | — | ||
| Q2 25 | 67.7% | — | ||
| Q1 25 | 68.8% | — | ||
| Q4 24 | 67.8% | — | ||
| Q3 24 | 68.8% | — | ||
| Q2 24 | 69.2% | — |
| Q1 26 | — | 21.4% | ||
| Q4 25 | 15.6% | 18.0% | ||
| Q3 25 | 20.7% | 19.3% | ||
| Q2 25 | 16.2% | 18.6% | ||
| Q1 25 | 19.8% | 20.4% | ||
| Q4 24 | 14.8% | 15.4% | ||
| Q3 24 | 17.4% | 17.3% | ||
| Q2 24 | 12.6% | 18.9% |
| Q1 26 | 25.7% | 12.9% | ||
| Q4 25 | 12.7% | 9.8% | ||
| Q3 25 | 14.9% | 13.6% | ||
| Q2 25 | 15.7% | 9.3% | ||
| Q1 25 | 14.4% | 10.6% | ||
| Q4 24 | 12.3% | 10.2% | ||
| Q3 24 | 11.1% | 9.7% | ||
| Q2 24 | 7.8% | 8.8% |
| Q1 26 | $0.90 | $0.39 | ||
| Q4 25 | $0.45 | $0.29 | ||
| Q3 25 | $0.51 | $0.37 | ||
| Q2 25 | $0.53 | $0.24 | ||
| Q1 25 | $0.45 | $0.28 | ||
| Q4 24 | $0.38 | $0.30 | ||
| Q3 24 | $0.32 | $0.27 | ||
| Q2 24 | $0.22 | $0.24 |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BSX
| Cardiovascular | $3.1B | 59% |
| Endoscopy | $673.0M | 13% |
| Urology | $633.0M | 12% |
| Other | $386.0M | 7% |
| Neuromodulation | $271.0M | 5% |
| LACA | $155.0M | 3% |
PCG
| Electric | $5.0B | 72% |
| Other | $1.9B | 28% |
